Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xandar Kardian is a private medtech and digital health company developing and commercializing contact-free monitoring systems based on ultra-wideband radar and proprietary signal processing. Its lead healthcare product, the FDA 510(k)-cleared XK300 sensor, continuously measures motion, resting heart rate, respiratory rate, and presence without wearables, cameras, or direct patient contact. The company markets its technology across acute care, long-term care, home health, and correctional health settings, and also applies the same radar stack to built-environment use cases such as occupancy detection and people counting. Xandar Kardian positions itself as both a healthcare monitoring company and a broader radar platform business serving health and building applications. The company is venture-backed and appears to be actively commercializing in North America and selected international markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Xandar Kardian.